From the Arrhythmia Unit and Electrophysiology Laboratories, Department of Cardiology and Cardiothoracic Surgery, San Raffaele Hospital, Milan, Italy.
Circ Arrhythm Electrophysiol. 2018 Mar;11(3):e005602. doi: 10.1161/CIRCEP.117.005602.
Catheter ablation of ventricular tachycardia (VT) is effective to prevent arrhythmia episode-related implantable cardioverter defibrillator shocks. However, recurrences in noninducible patients at programmed ventricular stimulation (PVS) are substantial.
From May 2013 to September 2015, 218 PVSs were performed 6 days (5-7) after ablation (186 noninvasive programmed stimulations and 32 invasive PVS) in 210 consecutive patients (ischemic, 48%; median left ventricular ejection fraction, 37%; syncope, 35% with trauma associated 6%), while patients were awake and under β-blocker therapy. After ablation, implantable cardioverter defibrillators were programmed according to noninvasive programmed stimulations results (class A-noninducible; class B-nondocumented inducible VT; and class C-documented inducible VT), with high and delayed VT detection intervals. Concordance between PVS end procedure and PVS day 6 was 67%. Positive predictive value and negative predictive value were higher for PVS day 6 (53% and 88% versus 43% and 71%). Ischemic and patients with preserved ejection fraction showed the highest negative predictive value (91% and 96%). Among 46 of 174 (26%) noninducible patients at PVS end procedure, but inducible at day 6, 59% had VT recurrence at 1-year follow-up; recurrences were 9% when both studies were noninducible. There were no inappropriate shocks; incidence of syncope was 3%; and none was harmful. The rate of appropriate shocks per patient per month according to noninvasive programmed stimulations results was significantly reduced, comparing the month before and after ablation (class A: 2 [0.75-4] versus 0; class B: 2 [1-4] versus 0; class C: 2 [1-4] versus 0; <0.001).
PVS at day 6 predicts VT recurrence more accurately allowing to identify patients who might benefit from a redo ablation and addressing implantable cardioverter defibrillator programming.
导管消融术治疗室性心动过速(VT)可有效预防与心律失常事件相关的植入式心脏复律除颤器(ICD)电击。然而,在程控心室刺激(PVS)中,非诱发性患者的复发率仍然很高。
2013 年 5 月至 2015 年 9 月,210 例连续患者(缺血性,48%;中位左心室射血分数,37%;晕厥,35%伴创伤相关 6%)在消融后 6 天(5-7 天)进行了 218 次 PVS(186 次非侵入性程控刺激和 32 次侵入性 PVS),患者处于清醒状态并接受β受体阻滞剂治疗。消融后,根据非侵入性程控刺激结果(A 级:非诱发性;B 级:无记录的诱发性 VT;C 级:有记录的诱发性 VT)对 ICD 进行程控,检测间期高且延迟。PVS 结束时与 PVS 第 6 天的一致性为 67%。PVS 第 6 天的阳性预测值和阴性预测值较高(53%和 88%,而 43%和 71%)。缺血性和射血分数保留患者的阴性预测值最高(91%和 96%)。在 174 例(26%)非诱发性患者中,PVS 结束时非诱发性但在第 6 天诱发性,59%在 1 年随访时出现 VT 复发;当两项研究均为非诱发性时,复发率为 9%。无不适当的电击;晕厥发生率为 3%;无有害。与消融前相比,根据非侵入性程控刺激结果,每个患者每月的适当电击次数明显减少(A 级:2 [0.75-4] 与 0;B 级:2 [1-4] 与 0;C 级:2 [1-4] 与 0;<0.001)。
PVS 第 6 天的预测结果更准确,可以识别出可能从再次消融中获益的患者,并对 ICD 进行编程。